Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Safety, Tolerability, and Impact of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
The study aimed to assess safety and tolerability of oral toll-like receptor (TLR) 8 agonist Selgantolimod (SLGN) administered for 24 weeks in participants with both chronic hepatitis B (CHB) and HIV who had received suppressive antiviral therapy for both viruses for ≥5 years and have qHBsAg level >1000 (3 log10) IU/mL at screening. The study also evaluated if TLR8 stimulation with SLGN will reduce hepatitis B surface antigen (HBsAg) titers in the blood.
The primary hypotheses of this study were:
- Administration of the oral TLR8 agonist SLGN will be safe and well-tolerated in participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
- TLR8 stimulation with SLGN will reduce HBsAg titers in the blood of participants with both CHB and HIV on suppressive antiviral therapy for both viruses.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
A5394 was a phase II, randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, and efficacy of 24 weeks of treatment with SLGN. Participants were randomized in a 3:1 ratio to receive SLGN or its placebo, and randomization was stratified by HBeAg status. Participants were planned to be on study for up to 48 weeks (24-week treatment phase and 24-week post-treatment follow-up). All participants were required to remain on their non-study-provided antiviral therapy throughout the study.
The primary efficacy analysis was planned to be conducted as a single-arm study of the SLGN study arm.
Accrual was terminated early and did not reach the target sample size of 48 due to ACTG Network funding disruptions.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 21040-360
- Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS (Site ID: 12101)
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 91350-180
- Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS (Site ID: 12201)
-
-
-
-
-
Lima, Peru, 04
- Barranco CRS (Site ID: 11301)
-
-
-
-
-
Chiang Mai, Thailand, 50200
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (Site ID: 31784)
-
-
Bangkok
-
Pathum Wan, Bangkok, Thailand, 10330
- Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (Site ID: 31802)
-
-
-
-
California
-
San Diego, California, United States, 92103
- UCSD Antiviral Research Center CRS (Site ID: 701)
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- The Ponce de Leon Center CRS (Site ID: 5802)
-
-
New York
-
New York, New York, United States, 10011
- Weill Cornell Chelsea CRS (Site ID: 7804)
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27401
- Greensboro CRS (Site ID: 3203)
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267-0405
- Cincinnati Clinical Research Site (Site ID: 2401)
-
Cleveland, Ohio, United States, 44106
- Case CRS (Site ID: 2501)
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Univ of Pittsburgh (Site ID: 1001)
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-1 infection
- Effective antiviral therapy for HIV (ART) and HBV that includes TDF, TAF, TDF/FTC, TDF/3TC (tenofovir disoproxil fumarate plus lamivudine), TAF/FTC, or entecavir (ETV), for ≥5 years immediately prior to study entry. ART is defined as including a minimum of two anti-HIV antivirals.
- CD4+ cell count ≥350 cells/mm3
- HIV-1 RNA <50 copies/mL measured on at least two occasions at least 12 weeks apart, with no documented value >200 copies/mL, over the 12 months prior to study entry.
- Positive or negative HBeAg
- Negative anti-HDV
- Current CHB infection
- HBV DNA level <50 IU/mL measured on at least two occasions at least 12 weeks apart, with no documented value ≥50 IU/mL, over the 12 months prior to study entry.
- Quantitative HBsAg >1000 IU/mL
- Hepatitis C virus (HCV) antibody negative, or if the participant is HCV antibody positive, an undetectable HCV RNA.
- Participants must agree to stay on an effective antiviral therapy for HIV (ART) and HBV throughout the study.
Exclusion Criteria:
- Receipt of treatment for HCV within 24 weeks prior to study entry
- Evidence of advanced fibrosis or cirrhosis (Metavir ≥F3 or equivalent).
- Current or prior history of clinical hepatic decompensation (e.g., ascites, encephalopathy, or variceal hemorrhage)
- History of HCC or cholangiocarcinoma
- Malignancy within 5 years prior to study entry. NOTE: A history of non-melanoma skin cancer (e.g., basal cell carcinoma or squamous cell skin cancer) is not exclusionary.
- History of solid organ transplantation
- Presence of any active or acute AIDS-defining opportunistic infections within 60 days prior to study entry
- History of uveitis or posterior synechiae
- Breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Arm A
Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks. |
Two 1.5 mg tablets taken orally once a week
Other Names:
|
|
Placebo Comparator: Arm B
Participants received matching Placebo for Selgantolimod once weekly for 24 weeks. |
Two matching placebo tablets taken orally once a week |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Time Frame: From study treatment initiation through Week 24
|
An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or diagnosis that occurs in a study participant during the conduct of the study REGARDLESS of the attribution. This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition. All AEs that are reported must have their severity graded. Adverse events were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), corrected Version 2.1, July 2017. Adverse events were graded on a scale from 1-5: 1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death. Higher scores/grades mean a worse outcome. The proportion of participants with Grade 2 or higher adverse events was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Time Frame: From study treatment initiation through Week 24
|
The proportion of participants who had premature discontinuation of Selgantolimod due to adverse event(s) was calculated, along with a two-sided 95% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From study treatment initiation through Week 24
|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Time Frame: Week 24
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Time Frame: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥1 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Time Frame: Week 24
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at Week 24 was calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
Week 24
|
|
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Time Frame: From Baseline (Entry) through Week 48
|
The proportion of participants who experienced ≥0.5 log10 IU/mL decline in quantitative HBsAg at any time during the study after SLGN treatment initiation will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Time Frame: From Baseline (Entry) through Week 48
|
Sustained HBsAg loss is defined as HBsAg converting from positive to negative after initiation of SLGN, without any subsequent positive HBsAg result. The proportion of participants who achieved HBsAg loss after SLGN initiation and who sustained HBsAg loss during follow-up will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Changes From Baseline in qHBsAg Levels
Time Frame: Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
The absolute change in qHBsAg level refers to the value at the follow-up time point minus the value at Baseline (Entry). |
Baseline (Entry) and Weeks 4, 12, 24, 36 and 48
|
|
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Time Frame: From Baseline (Entry) through Week 48
|
HBeAg loss is defined as HBeAg changing from positive to negative. The proportion of participants who lose HBeAg at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Time Frame: From Baseline (Entry) through Week 48
|
Developing anti-HBe, or anti-HBe gain, is defined as HBeAb changing from negative to positive. The proportion of participants who develop HBeAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Time Frame: From Baseline (Entry) through Week 48
|
Developing anti-HBs, or anti-HBs gain, is defined as HBsAb changing from negative to positive. The proportion of participants who develop HBsAb at any time during the study will be calculated, along with a two-sided 90% confidence interval constructed using the Clopper-Pearson exact method for binomial data. |
From Baseline (Entry) through Week 48
|
|
Number of Participants With Plasma HIV RNA >50 Copies/mL
Time Frame: Weeks 2, 4, 24 and 48
|
The number of participants with detectable plasma HIV RNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
|
Number of Participants With Serum HBV DNA >50 IU/mL
Time Frame: Weeks 2, 4, 24 and 48
|
The number of participants with detectable serum HBV DNA >50 copies/mL will be reported. |
Weeks 2, 4, 24 and 48
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Digestive System Diseases
- Liver Diseases
- Hepatitis, Viral, Human
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- DNA Virus Infections
- Hepadnaviridae Infections
- Hepatitis
- HIV Infections
- Hepatitis B
- selgantolimod
Other Study ID Numbers
Other Study ID Numbers
- A5394
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Individual participant data that underlie results in the publication, after deidentification
IPD Sharing Time Frame
Beginning 3 months following publication and available throughout period of funding of the Advancing Clinical Therapeutics Globally (ACTG) by NIH
IPD Sharing Access Criteria
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the ACTG.
For what types of analyses? To achieve aims in the proposal approved by the ACTG.
By what mechanism will data be made available? Researchers may submit a request for access to data using the ACTG "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an ACTG Data Use Agreement before receiving the data.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.